

The Effects of Rivastigmine on Neuropsychiatric Symptoms in the Early Stages of Parkinson's Disease: A Systematic Review

Dr Siobhan Reilly^{1*}, Dr Simran Dhaliwal², Mr Usman Arshad³, Dr Nusrat Husain⁴, Dr Antonella Macerollo⁵ and Dr Antonio Da Costa

¹Greater Manchester Mental Health NHS Foundation Trust, Manchester, United Kingdom; ²George Eliot Hospital NHS Trust, Nuneaton, United Kingdom; ³Pakistan Institute of Living and Learning, Lahore, Pakistan; ⁴University of Manchester, Manchester, United Kingdom; ⁵The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom and ⁶Frankston Hospital, Melbourne, Australia

*Corresponding author.

doi: 10.1192/bjo.2023.494

Aims. Neuropsychiatric symptoms including depression, apathy and psychosis are experienced by the majority of patients with Parkinson's disease. A subgroup of patients develop cognitive impairment, which may increase the risk of falls due to reduced attention. Acetylcholine deficit is thought to contribute to neuropsychiatric symptoms in Parkinson's disease. The acetylcholinesterase inhibitor rivastigmine is beneficial in Parkinson's disease dementia (PDD), but the consensus for the use of rivastigmine earlier in the disease course is unclear. This systematic review aims to assess the evidence for rivastigmine in the treatment of neuropsychiatric symptoms in Parkinson's disease without dementia.

Methods. EMBASE, MEDLINE, PsychINFO, Cochrane CENTRAL, NGLC, NICE Evidence and medRxiv.org were searched for studies with terms relating to Population (Parkinson's disease) and intervention (rivastigmine).

1922 references were identified, of which 358 were duplications.

Inclusion criteria were: diagnosis of Parkinson's disease, rivastigmine intervention and the presence of neuropsychiatric symptoms or falls. Articles were excluded if they only related to patients with dementia.

Following title and abstract review, 1331 articles were excluded.

After full text review, 9 articles remained, which underwent a risk of bias analysis.

Results. Outcomes were heterogenous, so were not suitable for meta-analysis. Therefore, the results are presented in narrative form. The articles included 6 Randomised Controlled Trials (RCTs), 2 open-label trials and 1 case-series.

Three of the studies focused on psychosis. Two of these studies indicated a benefit of rivastigmine on psychotic symptoms in Parkinson's disease. However, these studies were an open label trial and a case series, and the results were not reproduced during RCT.

One RCT indicated benefit of rivastigmine in rapid eye movement behaviour disorder (RBD).

One RCT showed improvements in apathy after treatment with rivastigmine.

Two RCTs demonstrated a reduction in falls with rivastigmine treatment compared to placebo.

One RCT showed a significant improvement on a performance-based measure of cognitive ability.

One study identified brain areas that were hypoactive in hallucinating Parkinson's patients, and the reduced activity could be restored with rivastigmine. This restoration of activity was associated with improved attention compared to baseline.

Conclusion. There is evidence that rivastigmine is beneficial for RBD and apathy in Parkinson's disease, independently from the presence of dementia. There is high level evidence that rivastigmine reduces falls, which may be due to improved attention.

The impact of rivastigmine on psychotic symptoms is less clear, but is supported by current theoretical models which involve acetylcholine dysfunction in the generation of visual hallucinations in Parkinson's disease.

Abstracts were reviewed by the RCPsych Academic Faculty rather than by the standard *BJPsych Open* peer review process and should not be quoted as peer-reviewed by *BJPsych Open* in any subsequent publication.

Rapid Clozapine Blood Level Determination in a National Health Service Trust

Professor David Taylor^{1*}, Dr Jodi Courtney², Dr Mary Rose Hilaire² and Mr Matthew Atkins¹

¹Maudsley Hospital, London, United Kingdom and ²Saladax, Bethlehem, United States of America

*Corresponding author.

doi: 10.1192/bjo.2023.495

Aims. The use of clozapine demands regular monitoring of patients' clozapine blood levels. Assays are usually performed in a central laboratory with results available only after several days. The South London and Maudsley NHS Trust wanted to implement a clozapine Point-of-Care (POC) capillary blood test that would provide the benefits of immediate results.

Methods. The MyCare Insite, a small (2.2 kg) tabletop analyser was used. The Insite can readily be connected to electronic health records. Insite device has been fully validated but to achieve the benefit of clozapine POC testing, other factors beyond the test validation needed to be considered. We developed tools, software, and processes to guide health professionals on why and when to measure clozapine blood levels, on what to do with test results, and systems for documentation and tracking of patients' test results. In addition, the device supplier conducted staff training to ensure consistent and correct testing. Finally, users were certified as qualified based on demonstrated proficiency.

Results. We have fully implemented POC capillary clozapine testing across four geographic sites. Patients and staff preferred capillary finger stick testing over venous draws. Patients' engagement with their results was better than with laboratory testing. Real-time testing for adherence was possible for patients admitted on clozapine. It was also possible to make rapid dose adjustments based on near immediate plasma level results. Patient safety was increased since toxic levels could be quickly detected. Clinical decision-making was expedited as results were available immediately (< 7 minutes). The utility of the testing meant that the length of hospital stays was reduced as discharges were not delayed pending a laboratory result.

Conclusion. Clozapine POC blood level testing was successfully implemented at our institution achieving the expected benefits of clozapine POC testing with near immediate results. The new process improves clozapine management, patient engagement and reduces inpatient bed stays.

Abstracts were reviewed by the RCPsych Academic Faculty rather than by the standard *BJPsych Open* peer review process and should not be quoted as peer-reviewed by *BJPsych Open* in any subsequent publication.

Multimorbidity and Polypharmacy in Psychosis: Identifying Potentially Significant Drug Interactions in an Old Age Inpatient Psychiatry Setting

Dr Abhinav Tewari^{1*} and Dr Ashish Pathak²

¹Essex Partnership University NHS Foundation Trust, Grays, Thurrock, United Kingdom and ²Essex Partnership University NHS Foundation Trust, Basildon, United Kingdom

*Corresponding author.

doi: 10.1192/bjo.2023.496

Aims. To determine potentially significant drug interactions in an old age setting among inpatients with psychosis and medical comorbidities over the past 12 months

Methods. Study setting: old age inpatient functional ward

Sample size: 11

Inclusion criteria:

- Inpatients on psychotropic medications with diagnosis ranging from F20 to F29 (ICD-10)
- Comorbid chronic medical condition(s) requiring long term drug treatment

Exclusion criteria:

- Patients with other/co-existing mental health diagnosis excluded
- Antibiotics, OTC medications, herbal treatments, emergency treatments and other medications requiring short-term administration excluded from analysis

Study tools:

- Lexicomp® interaction checker
 - Category X: Avoid combination
 - Category D: Consider therapy modification
 - Further categories (In order of decreasing risk ratings: C, B, A) excluded from the analysis

Results. Out of the total 67 inpatients admitted between January 2022 and December 2022, 17 patients had diagnosis ranging between F20 and F29. 4 patients were excluded due to no medical comorbidities and 2 were excluded due to lack of data. Among

the 11 patients included in the analysis, the most common medical comorbidities were, in decreasing order, hypertension, hypercholesterolemia and chronic pain. A total of 114 interactions were noted between psychotropic medications and other physical health medications, as follows:

No significant interactions: (category A, B, C): 103

Category D (consider therapy modification): 10

- 7 of these interactions were associated with administering Buprenorphine with other medications (Flupentixol, Gabapentin, Nortriptyline, Olanzapine, Amisulpride, Aripiprazole and Pregabalin) leading to additive CNS depressant effects.
- Interaction of codeine with Valproate and Flupentixol carried risk of CNS depression.
- Carbamazepine interacted with Risperidone via CYP enzyme induction.

Category X (avoid combination): 1

- The interaction between Flupentixol and Glycopyrronium was associated with risk of severe anticholinergic effects

Conclusion. This study is a preliminary investigation towards understanding the drug interactions in a population with long term mental health and physical health ailments. Awareness regarding the potential interactions can help avoid combinations with possible detrimental effects. The limitations of this study, in terms of sample size and quality of available data, can be overcome by conducting a planned study on a larger population.

Financial Sponsorship: none

Conflict of interests: none

Abstracts were reviewed by the RCPsych Academic Faculty rather than by the standard *BJPsych Open* peer review process and should not be quoted as peer-reviewed by *BJPsych Open* in any subsequent publication.